Actively Recruiting
Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Led by Emory University · Updated on 2025-09-11
28
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
E
Emory University
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating how well atovaquone, a drug normally used to treat certain infections, works in treating patients with platinum-resistant ovarian cancer. This phase II clinical trial aims to assess whether repurposing atovaquone can improve outcomes compared to standard chemotherapy for this hard-to-treat cancer type. The study focuses on patients whose cancer has progressed within six months after their last platinum-based chemotherapy. Participants receive atovaquone orally throughout the study. They also undergo procedures such as computed tomography (CT) scans, biopsies, or paracentesis to monitor the cancer and treatment effects. After finishing the treatment phase, patients are followed for 30 days and then every six months to track their progress and health. During the trial, researchers will evaluate progression free survival, clinical benefit rate at six months, overall survival, and the impact of atovaquone on specific cancer-related gene activity and immune responses. Safety is monitored by tracking adverse events up to 30 days post-treatment. The total follow-up may last up to one year or more to understand treatment effects over time.
CONDITIONS
Brief Title
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
- Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- There will be no limitations on number of prior lines of therapy
- Trial is open to non-English speaking patients
- Trial is open to patients referred from community practice
You will not qualify if you...
- Patients who are younger than 18 years old
- Patients who are pregnant or breastfeeding
- Patients who are incarcerated
- Patients who are unable to provide consent or lack decision-making capacity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year or until disease progression or discontinuation
Participants receive atovaquone orally and undergo CT scans and biopsy or paracentesis throughout the study to monitor disease progression and biological effects.
Visits for CT scans and biopsy or paracentesis occur throughout the treatment period
Duration - 30 days plus every 6 months thereafter
After completing treatment, participants are followed up for 30 days and then every 6 months to assess overall survival and monitor adverse events.
1 visit 30 days post-treatment and follow-up visits every 6 months
Trial Site Locations
Total: 1 location
1
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Actively Recruiting
Research Team
N
Namita Khanna, MD, MSPH
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here